Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans


Allabi A., Gala J., Horsmans Y., Babaoglu M., Bozkurt A., Heusterspreute M., ...Daha Fazla

CLINICAL PHARMACOLOGY & THERAPEUTICS, cilt.76, sa.2, ss.113-118, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 76 Sayı: 2
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1016/j.clpt.2004.04.001
  • Dergi Adı: CLINICAL PHARMACOLOGY & THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.113-118
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background and Aim: Previous data indicate that the urinary losartan/E-3174 ratio is a marker for cytochrome P450 (CYP) 2C9 activity in vivo. The functional impact of CYP2C9(star)5, (star)6, (star)8, and (star)11 polymorphisms in vivo has not been investigated previously in humans.